25 XP   0   0   10

Ovid Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Ovid Therapeutics Inc together

PenkeI guess you are interested in Ovid Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Ovid Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Ovid Therapeutics Inc

I send you an email if I find something interesting about Ovid Therapeutics Inc.

Quick analysis of Ovid Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Ovid Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€1.17
Expected worth in 1 year
€0.57
How sure are you?
22.2%

+ What do you gain per year?

Total Gains per Share
€-0.59
Return On Investment
-20.2%

For what price can you sell your share?

Current Price per Share
€2.92
Expected price per share
€2.26 - €3.66
How sure are you?
50%

1. Valuation of Ovid Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

€2.92

Intrinsic Value Per Share

€2.19 - €2.61

Total Value Per Share

€3.35 - €3.77

2. Growth of Ovid Therapeutics Inc (5 min.)




Is Ovid Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$87.7m$147.8m-$42.6m-40.6%

How much money is Ovid Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$13m-$13.5m$457.4k3.5%
Net Profit Margin-14,470.4%-33,442.9%--

How much money comes from the company's main activities?

3. Financial Health of Ovid Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#399 / 1009

Most Revenue
#632 / 1009

Most Profit
#10 / 1009

What can you expect buying and holding a share of Ovid Therapeutics Inc? (5 min.)

Welcome investor! Ovid Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Ovid Therapeutics Inc.

What can you expect buying and holding a share of Ovid Therapeutics Inc?

First you should know what it really means to hold a share of Ovid Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Ovid Therapeutics Inc is €2.92. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Ovid Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Ovid Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €1.17. Based on the TTM, the Book Value Change Per Share is €-0.15 per quarter. Based on the YOY, the Book Value Change Per Share is €-0.16 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Ovid Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.22-7.4%-0.18-6.2%-0.19-6.6%-0.08-2.7%-0.08-2.7%
Usd Book Value Change Per Share-0.19-6.5%-0.16-5.4%-0.17-5.7%0.072.4%0.072.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.19-6.5%-0.16-5.4%-0.17-5.7%0.072.4%0.072.4%
Usd Price Per Share3.20-3.15-2.18-3.26-3.26-
Price to Earnings Ratio-3.69--4.41--2.84--3.45--3.45-
Price-to-Total Gains Ratio-16.75--20.57--13.01--11.09--11.09-
Price to Book Ratio2.57-2.17-1.04-3.22-3.22-
Price-to-Total Gains Ratio-16.75--20.57--13.01--11.09--11.09-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.111552
Number of shares321
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.160.07
Usd Total Gains Per Share-0.160.07
Gains per Quarter (321 shares)-50.4722.14
Gains per Year (321 shares)-201.9088.57
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-202-21208979
20-404-4140177168
30-606-6160266257
40-808-8180354346
50-1009-10200443435
60-1211-12220531524
70-1413-14240620613
80-1615-16260709702
90-1817-18280797791
100-2019-20300886880

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%1.017.00.05.6%1.017.00.05.6%1.017.00.05.6%
Book Value Change Per Share0.04.00.00.0%1.011.00.08.3%4.014.00.022.2%4.014.00.022.2%4.014.00.022.2%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.018.00.0%0.00.018.00.0%0.00.018.00.0%
Total Gains per Share0.04.00.00.0%1.011.00.08.3%4.014.00.022.2%4.014.00.022.2%4.014.00.022.2%

Fundamentals of Ovid Therapeutics Inc

About Ovid Therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Fundamental data was last updated by Penke on 2024-04-18 03:06:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Ovid Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Ovid Therapeutics Inc earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Ovid Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -10,823.5% means that €-108.23 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Ovid Therapeutics Inc:

  • The MRQ is -10,823.5%. The company is making a huge loss. -2
  • The TTM is -14,470.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-10,823.5%TTM-14,470.4%+3,646.9%
TTM-14,470.4%YOY-33,442.9%+18,972.5%
TTM-14,470.4%5Y-10,677.4%-3,793.0%
5Y-10,677.4%10Y-10,677.4%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-10,823.5%-200.1%-10,623.4%
TTM-14,470.4%-216.8%-14,253.6%
YOY-33,442.9%-288.3%-33,154.6%
5Y-10,677.4%-449.1%-10,228.3%
10Y-10,677.4%-605.5%-10,071.9%
1.1.2. Return on Assets

Shows how efficient Ovid Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Ovid Therapeutics Inc to the Biotechnology industry mean.
  • -10.6% Return on Assets means that Ovid Therapeutics Inc generated €-0.11 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Ovid Therapeutics Inc:

  • The MRQ is -10.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -9.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-10.6%TTM-9.5%-1.1%
TTM-9.5%YOY-7.8%-1.7%
TTM-9.5%5Y-11.8%+2.3%
5Y-11.8%10Y-11.8%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-10.6%-13.3%+2.7%
TTM-9.5%-12.8%+3.3%
YOY-7.8%-11.7%+3.9%
5Y-11.8%-13.9%+2.1%
10Y-11.8%-15.7%+3.9%
1.1.3. Return on Equity

Shows how efficient Ovid Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Ovid Therapeutics Inc to the Biotechnology industry mean.
  • -17.5% Return on Equity means Ovid Therapeutics Inc generated €-0.17 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Ovid Therapeutics Inc:

  • The MRQ is -17.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -12.7%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-17.5%TTM-12.7%-4.7%
TTM-12.7%YOY-9.1%-3.6%
TTM-12.7%5Y-16.9%+4.2%
5Y-16.9%10Y-16.9%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-17.5%-16.9%-0.6%
TTM-12.7%-16.1%+3.4%
YOY-9.1%-15.1%+6.0%
5Y-16.9%-19.3%+2.4%
10Y-16.9%-20.2%+3.3%

1.2. Operating Efficiency of Ovid Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Ovid Therapeutics Inc is operating .

  • Measures how much profit Ovid Therapeutics Inc makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Ovid Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Ovid Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-4,724.0%+4,724.0%
TTM-4,724.0%YOY-35,689.4%+30,965.4%
TTM-4,724.0%5Y-9,010.0%+4,286.0%
5Y-9,010.0%10Y-9,010.0%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--296.2%+296.2%
TTM-4,724.0%-232.5%-4,491.5%
YOY-35,689.4%-298.2%-35,391.2%
5Y-9,010.0%-492.1%-8,517.9%
10Y-9,010.0%-632.4%-8,377.6%
1.2.2. Operating Ratio

Measures how efficient Ovid Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 129.49 means that the operating costs are €129.49 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Ovid Therapeutics Inc:

  • The MRQ is 129.490. The company is inefficient in keeping operating costs low. -1
  • The TTM is 164.231. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ129.490TTM164.231-34.741
TTM164.231YOY357.649-193.418
TTM164.2315Y116.435+47.796
5Y116.43510Y116.4350.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ129.4903.231+126.259
TTM164.2313.310+160.921
YOY357.6493.890+353.759
5Y116.4355.739+110.696
10Y116.4357.876+108.559

1.3. Liquidity of Ovid Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Ovid Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 9.55 means the company has €9.55 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Ovid Therapeutics Inc:

  • The MRQ is 9.552. The company is very able to pay all its short-term debts. +2
  • The TTM is 11.999. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ9.552TTM11.999-2.447
TTM11.999YOY18.307-6.308
TTM11.9995Y12.053-0.054
5Y12.05310Y12.0530.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.5523.890+5.662
TTM11.9994.173+7.826
YOY18.3075.344+12.963
5Y12.0536.126+5.927
10Y12.0536.448+5.605
1.3.2. Quick Ratio

Measures if Ovid Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Ovid Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 6.87 means the company can pay off €6.87 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Ovid Therapeutics Inc:

  • The MRQ is 6.867. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 5.219. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ6.867TTM5.219+1.648
TTM5.219YOY8.174-2.955
TTM5.2195Y3.348+1.871
5Y3.34810Y3.3480.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.8673.514+3.353
TTM5.2193.998+1.221
YOY8.1745.380+2.794
5Y3.3486.105-2.757
10Y3.3486.404-3.056

1.4. Solvency of Ovid Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Ovid Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Ovid Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.39 means that Ovid Therapeutics Inc assets are financed with 39.0% credit (debt) and the remaining percentage (100% - 39.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Ovid Therapeutics Inc:

  • The MRQ is 0.390. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.231. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.390TTM0.231+0.159
TTM0.231YOY0.141+0.090
TTM0.2315Y0.186+0.045
5Y0.18610Y0.1860.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3900.339+0.051
TTM0.2310.336-0.105
YOY0.1410.271-0.130
5Y0.1860.366-0.180
10Y0.1860.389-0.203
1.4.2. Debt to Equity Ratio

Measures if Ovid Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Ovid Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 64.0% means that company has €0.64 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Ovid Therapeutics Inc:

  • The MRQ is 0.640. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.323. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.640TTM0.323+0.318
TTM0.323YOY0.165+0.158
TTM0.3235Y0.255+0.068
5Y0.25510Y0.2550.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6400.388+0.252
TTM0.3230.402-0.079
YOY0.1650.335-0.170
5Y0.2550.426-0.171
10Y0.2550.461-0.206

2. Market Valuation of Ovid Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Ovid Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Ovid Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -3.69 means the investor is paying €-3.69 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Ovid Therapeutics Inc:

  • The EOD is -3.590. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.688. Based on the earnings, the company is expensive. -2
  • The TTM is -4.406. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.590MRQ-3.688+0.098
MRQ-3.688TTM-4.406+0.718
TTM-4.406YOY-2.839-1.567
TTM-4.4065Y-3.451-0.956
5Y-3.45110Y-3.4510.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.590-2.264-1.326
MRQ-3.688-2.629-1.059
TTM-4.406-2.680-1.726
YOY-2.839-4.145+1.306
5Y-3.451-6.257+2.806
10Y-3.451-6.254+2.803
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Ovid Therapeutics Inc:

  • The EOD is -4.617. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -4.744. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -4.922. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.617MRQ-4.744+0.126
MRQ-4.744TTM-4.922+0.178
TTM-4.922YOY-2.802-2.120
TTM-4.9225Y-6.413+1.492
5Y-6.41310Y-6.4130.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.617-2.973-1.644
MRQ-4.744-3.333-1.411
TTM-4.922-3.553-1.369
YOY-2.802-5.605+2.803
5Y-6.413-8.376+1.963
10Y-6.413-8.865+2.452
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Ovid Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.57 means the investor is paying €2.57 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Ovid Therapeutics Inc:

  • The EOD is 2.506. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.575. Based on the equity, the company is underpriced. +1
  • The TTM is 2.166. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.506MRQ2.575-0.069
MRQ2.575TTM2.166+0.409
TTM2.166YOY1.036+1.131
TTM2.1665Y3.221-1.055
5Y3.22110Y3.2210.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.5061.896+0.610
MRQ2.5752.115+0.460
TTM2.1662.093+0.073
YOY1.0362.884-1.848
5Y3.2213.542-0.321
10Y3.2213.916-0.695
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Ovid Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.179-0.148-18%-0.158-12%0.065-377%0.065-377%
Book Value Per Share--1.1651.396-17%1.962-41%1.553-25%1.553-25%
Current Ratio--9.55211.999-20%18.307-48%12.053-21%12.053-21%
Debt To Asset Ratio--0.3900.231+69%0.141+176%0.186+109%0.186+109%
Debt To Equity Ratio--0.6400.323+98%0.165+289%0.255+151%0.255+151%
Dividend Per Share----0%-0%-0%-0%
Eps---0.203-0.171-16%-0.180-12%-0.075-63%-0.075-63%
Free Cash Flow Per Share---0.158-0.152-4%-0.188+19%-0.030-81%-0.030-81%
Free Cash Flow To Equity Per Share--0.240-0.051+121%-0.187+178%0.035+581%0.035+581%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--2.606--------
Intrinsic Value_10Y_min--2.188--------
Intrinsic Value_1Y_max--0.098--------
Intrinsic Value_1Y_min--0.096--------
Intrinsic Value_3Y_max--0.419--------
Intrinsic Value_3Y_min--0.397--------
Intrinsic Value_5Y_max--0.889--------
Intrinsic Value_5Y_min--0.815--------
Market Cap206472919.680-3%212129712.000208912411.368+2%144875754.558+46%216503905.228-2%216503905.228-2%
Net Profit Margin---108.235-144.704+34%-334.429+209%-106.774-1%-106.774-1%
Operating Margin----47.2400%-356.8940%-90.1000%-90.1000%
Operating Ratio--129.490164.231-21%357.649-64%116.435+11%116.435+11%
Pb Ratio2.506-3%2.5752.166+19%1.036+149%3.221-20%3.221-20%
Pe Ratio-3.590+3%-3.688-4.406+19%-2.839-23%-3.451-6%-3.451-6%
Price Per Share2.920-3%3.0002.955+2%2.049+46%3.062-2%3.062-2%
Price To Free Cash Flow Ratio-4.617+3%-4.744-4.922+4%-2.802-41%-6.413+35%-6.413+35%
Price To Total Gains Ratio-16.304+3%-16.751-20.566+23%-13.014-22%-11.087-34%-11.087-34%
Quick Ratio--6.8675.219+32%8.174-16%3.348+105%3.348+105%
Return On Assets---0.106-0.095-11%-0.078-26%-0.118+11%-0.118+11%
Return On Equity---0.175-0.127-27%-0.091-48%-0.169-3%-0.169-3%
Total Gains Per Share---0.179-0.148-18%-0.158-12%0.065-377%0.065-377%
Usd Book Value--87793290.840105179490.422-17%147860709.377-41%116998678.482-25%116998678.482-25%
Usd Book Value Change Per Share---0.191-0.157-18%-0.168-12%0.069-377%0.069-377%
Usd Book Value Per Share--1.2421.487-17%2.091-41%1.655-25%1.655-25%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.217-0.182-16%-0.192-12%-0.080-63%-0.080-63%
Usd Free Cash Flow---11913039.022-11479124.796-4%-14160895.696+19%-2006396.259-83%-2006396.259-83%
Usd Free Cash Flow Per Share---0.168-0.162-4%-0.200+19%-0.032-81%-0.032-81%
Usd Free Cash Flow To Equity Per Share--0.256-0.054+121%-0.200+178%0.038+581%0.038+581%
Usd Market Cap220017543.211-3%226045421.107222617065.554+2%154379604.057+46%230706561.411-2%230706561.411-2%
Usd Price Per Share3.112-3%3.1973.148+2%2.183+46%3.263-2%3.263-2%
Usd Profit---15321406.409-13084203.799-15%-13541649.561-12%-5461584.562-64%-5461584.562-64%
Usd Revenue--141557.20297919.739+45%375671.612-62%12382517.402-99%12382517.402-99%
Usd Total Gains Per Share---0.191-0.157-18%-0.168-12%0.069-377%0.069-377%
 EOD+3 -5MRQTTM+10 -22YOY+12 -205Y+7 -2510Y+7 -25

3.2. Fundamental Score

Let's check the fundamental score of Ovid Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-3.590
Price to Book Ratio (EOD)Between0-12.506
Net Profit Margin (MRQ)Greater than0-108.235
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than16.867
Current Ratio (MRQ)Greater than19.552
Debt to Asset Ratio (MRQ)Less than10.390
Debt to Equity Ratio (MRQ)Less than10.640
Return on Equity (MRQ)Greater than0.15-0.175
Return on Assets (MRQ)Greater than0.05-0.106
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Ovid Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.111
Ma 20Greater thanMa 502.891
Ma 50Greater thanMa 1002.983
Ma 100Greater thanMa 2003.017
OpenGreater thanClose2.920
Total1/5 (20.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Total Other Income Expense Net 6278151,4412141,655-926729-2,677-1,948



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets144,027
Total Liabilities56,230
Total Stockholder Equity87,797
 As reported
Total Liabilities 56,230
Total Stockholder Equity+ 87,797
Total Assets = 144,027

Assets

Total Assets144,027
Total Current Assets109,598
Long-term Assets34,429
Total Current Assets
Cash And Cash Equivalents 27,042
Short-term Investments 78,792
Other Current Assets 3,764
Total Current Assets  (as reported)109,598
Total Current Assets  (calculated)109,598
+/-0
Long-term Assets
Property Plant Equipment 14,663
Long Term Investments 17,626
Long-term Assets Other 1,957
Long-term Assets  (as reported)34,429
Long-term Assets  (calculated)34,246
+/- 183

Liabilities & Shareholders' Equity

Total Current Liabilities11,474
Long-term Liabilities44,756
Total Stockholder Equity87,797
Total Current Liabilities
Accounts payable 3,703
Total Current Liabilities  (as reported)11,474
Total Current Liabilities  (calculated)3,703
+/- 7,771
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt16,002
Long-term Liabilities Other 30,000
Long-term Liabilities  (as reported)44,756
Long-term Liabilities  (calculated)46,002
+/- 1,246
Total Stockholder Equity
Total Stockholder Equity (as reported)87,797
Total Stockholder Equity (calculated)0
+/- 87,797
Other
Capital Stock71
Common Stock Shares Outstanding 70,692
Net Invested Capital 87,797
Net Working Capital 98,123
Property Plant and Equipment Gross 15,664



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-30
> Total Assets 
40,694
80,844
61,723
45,355
91,599
75,926
237,456
217,999
207,086
194,545
191,096
177,330
165,032
155,266
143,367
136,230
125,029
144,027
144,027125,029136,230143,367155,266165,032177,330191,096194,545207,086217,999237,45675,92691,59945,35561,72380,84440,694
   > Total Current Assets 
39,150
79,813
60,737
44,111
90,347
74,843
236,662
215,873
205,056
190,479
170,087
156,081
140,498
131,381
119,519
102,171
91,713
109,598
109,59891,713102,171119,519131,381140,498156,081170,087190,479205,056215,873236,66274,84390,34744,11160,73779,81339,150
       Cash And Cash Equivalents 
37,908
41,897
27,337
41,254
86,866
72,034
233,051
212,167
201,780
187,798
166,668
72,812
58,257
129,001
63,052
71,623
57,437
27,042
27,04257,43771,62363,052129,00158,25772,812166,668187,798201,780212,167233,05172,03486,86641,25427,33741,89737,908
       Short-term Investments 
0
34,842
30,997
0
0
0
0
0
0
0
0
79,554
79,600
84,134
54,668
24,894
29,635
78,792
78,79229,63524,89454,66884,13479,60079,5540000000030,99734,8420
       Net Receivables 
0
1,131
374
563
649
142
1,024
0
0
0
1,000
1,000
0
0
0
0
0
0
0000001,0001,0000001,0241426495633741,1310
       Other Current Assets 
0
0
0
0
0
0
0
0
0
0
2,419
2,715
2,640
2,379
1,799
5,653
4,642
3,764
3,7644,6425,6531,7992,3792,6402,7152,4190000000000
   > Long-term Assets 
1,544
1,031
986
1,245
1,252
1,082
794
2,126
2,030
4,066
21,009
21,249
24,534
23,885
23,848
34,059
33,315
34,429
34,42933,31534,05923,84823,88524,53421,24921,0094,0662,0302,1267941,0821,2521,2459861,0311,544
       Property Plant Equipment 
72
68
109
116
138
136
128
114
105
243
15,949
16,681
16,337
16,071
15,722
15,368
15,012
14,663
14,66315,01215,36815,72216,07116,33716,68115,9492431051141281361381161096872
       Long Term Investments 
0
0
0
0
0
0
0
1,608
1,632
1,632
2,784
2,229
5,952
5,623
5,982
16,471
16,124
17,626
17,62616,12416,4715,9825,6235,9522,2292,7841,6321,6321,6080000000
       Other Assets 
1,120
495
441
753
753
628
403
178
96
2,027
2,031
2,011
1,969
1,931
0
0
0
0
00001,9311,9692,0112,0312,027961784036287537534414951,120
> Total Liabilities 
10,648
10,820
10,278
14,872
27,956
32,294
16,346
11,290
10,064
14,798
26,100
25,182
22,981
22,993
22,419
25,531
23,737
56,230
56,23023,73725,53122,41922,99322,98125,18226,10014,79810,06411,29016,34632,29427,95614,87210,27810,82010,648
   > Total Current Liabilities 
10,361
10,534
9,992
14,586
17,959
22,063
16,346
11,290
10,064
14,798
10,228
9,215
6,732
6,992
6,721
10,142
8,663
11,474
11,4748,66310,1426,7216,9926,7329,21510,22814,79810,06411,29016,34622,06317,95914,5869,99210,53410,361
       Accounts payable 
5,342
3,256
3,992
4,634
3,162
5,446
3,148
910
3,141
7,127
2,257
4,617
1,033
1,953
1,831
3,763
1,217
3,703
3,7031,2173,7631,8311,9531,0334,6172,2577,1273,1419103,1485,4463,1624,6343,9923,2565,342
       Other Current Liabilities 
338
11
11
11
3,377
4,584
0
0
1,561
0
0
0
285
0
0
0
0
0
000002850001,561004,5843,377111111338
   > Long-term Liabilities 
287
287
287
287
9,997
10,231
0
0
0
0
15,872
15,967
16,249
16,002
15,698
15,390
15,073
44,756
44,75615,07315,39015,69816,00216,24915,96715,872000010,2319,997287287287287
       Other Liabilities 
287
287
287
287
9,997
10,231
0
0
0
0
0
0
0
0
0
0
0
0
00000000000010,2319,997287287287287
> Total Stockholder Equity
30,047
70,024
51,445
30,483
63,643
43,632
221,110
206,710
197,022
179,746
164,996
152,147
142,051
132,273
120,948
110,699
101,292
87,797
87,797101,292110,699120,948132,273142,051152,147164,996179,746197,022206,710221,11043,63263,64330,48351,44570,02430,047
   Common Stock
37
55
55
57
63
66
68
68
68
70
70
70
70
70
0
0
0
0
00007070707070686868666357555537
   Retained Earnings Total Equity000000000000000000
   Accumulated Other Comprehensive Income 000000000000000000
   Capital Surplus 000000000000000000
   Treasury Stock000000000000000000
   Other Stockholders Equity 
0
2
66
0
0
0
0
0
0
0
0
-90
-83
-42
0
0
0
0
0000-42-83-90000000006620



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue392
Cost of Revenue--
Gross Profit-392
 
Operating Income (+$)
Gross Profit-
Operating Expense-59,674
Operating Income-59,282-59,674
 
Operating Expense (+$)
Research Development28,588
Selling General Administrative31,086
Selling And Marketing Expenses-
Operating Expense59,67459,674
 
Net Interest Income (+$)
Interest Income4,900
Interest Expense--
Other Finance Cost-0
Net Interest Income4,900
 
Pretax Income (+$)
Operating Income-59,282
Net Interest Income4,900
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-52,339-61,282
EBIT - interestExpense = 0
-52,339
-52,339
Interest Expense-
Earnings Before Interest and Taxes (EBIT)--52,339
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-52,339
Tax Provision-0
Net Income From Continuing Ops-52,339-52,339
Net Income-52,339
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net2,000-4,900
 

Technical Analysis of Ovid Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Ovid Therapeutics Inc. The general trend of Ovid Therapeutics Inc is BEARISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Ovid Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-71.4%) Bearish trend (71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Ovid Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 3.02 < 3.62 < 3.66.

The bearish price targets are: 2.46 > 2.46 > 2.26.

Tweet this
Ovid Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Ovid Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 2/14.
The longshort score for the Moving Averages is -10/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Ovid Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Ovid Therapeutics Inc. The current macd is 0.01915121.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Ovid Therapeutics Inc price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Ovid Therapeutics Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Ovid Therapeutics Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Ovid Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartOvid Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Ovid Therapeutics Inc. The current adx is 16.44.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Ovid Therapeutics Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Ovid Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Ovid Therapeutics Inc. The current sar is 2.82658988.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Ovid Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Ovid Therapeutics Inc. The current rsi is 51.11. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending down: The RSI is trending down. -1
Ovid Therapeutics Inc Daily Relative Strength Index (RSI) ChartOvid Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Ovid Therapeutics Inc. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Ovid Therapeutics Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Ovid Therapeutics Inc Daily Stochastic Oscillator ChartOvid Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Ovid Therapeutics Inc. The current cci is 27.08.

Ovid Therapeutics Inc Daily Commodity Channel Index (CCI) ChartOvid Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Ovid Therapeutics Inc. The current cmo is 3.18185362.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Ovid Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartOvid Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Ovid Therapeutics Inc. The current willr is -41.66666667.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Ovid Therapeutics Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Ovid Therapeutics Inc Daily Williams %R ChartOvid Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Ovid Therapeutics Inc.

Ovid Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Ovid Therapeutics Inc. The current atr is 0.0643901.

Ovid Therapeutics Inc Daily Average True Range (ATR) ChartOvid Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Ovid Therapeutics Inc. The current obv is -1,682.

Ovid Therapeutics Inc Daily On-Balance Volume (OBV) ChartOvid Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Ovid Therapeutics Inc. The current mfi is 50.11.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Ovid Therapeutics Inc Daily Money Flow Index (MFI) ChartOvid Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Ovid Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-30 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-01 00:00:00RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-04 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-06 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-07 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-08 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-11 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-14 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-19 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-20 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-21 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-22 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-27 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-28 00:00:00WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-02 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-03 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-04 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-08 00:00:00BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-09 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-12 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-18 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-23 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-24 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-25 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-29 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-30 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-31 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-02 00:00:00MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-05 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-06 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-07 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-08 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-12 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-14 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-15 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-16 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-19 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-21 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-22 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-23 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-29 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-12 00:00:00BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-13 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-14 00:00:00MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-21 00:00:00RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-22 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-25 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-26 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-27 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-28 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-02 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-03 00:00:00MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-05 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-08 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-10 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-11 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-12 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-15 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-17 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-18 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-19 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-22 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-23 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Ovid Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Ovid Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.111
Ma 20Greater thanMa 502.891
Ma 50Greater thanMa 1002.983
Ma 100Greater thanMa 2003.017
OpenGreater thanClose2.920
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Ovid Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Ovid Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Ovid Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Ovid Therapeutics Inc

I send you an email if I find something interesting about Ovid Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Ovid Therapeutics Inc.

Receive notifications about Ovid Therapeutics Inc in your mailbox!